Our lead product is a personalised tumour-derived T cell therapy targeting clonal cancer neoantigens. Our lead indications, advanced non-small cell lung cancer and recurrent metastatic melanoma, were selected for their high mutational burden, high level of T cell infiltration and high unmet medical need. Deaths from non-small cell lung cancer outnumber those resulting from breast cancer, colon cancer and prostate cancer combined, and there are limited approved treatment options for lung cancer and melanoma patients whose disease have not responded well to other therapies.